Merck's Crown Jewel Cancer Drug Keytruda Scores FDA Approval For Third Indication In Cervical Cancer
Portfolio Pulse from Vandana Singh
The FDA has approved Merck & Co Inc's Keytruda for a third indication in cervical cancer, in combination with chemoradiotherapy for certain stages. The approval is based on the Phase 3 KEYNOTE-A18 trial, which showed a 41% reduction in the risk of disease progression or death. Keytruda now has 39 indications in the U.S. and is expected to generate nearly $25 billion in sales in 2023. Merck's stock (MRK) saw a slight increase of 0.01% to $118.64.
January 16, 2024 | 4:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck's Keytruda gains FDA approval for a new cervical cancer indication, potentially boosting its sales and reinforcing its market position.
The FDA approval of Keytruda for a new indication is a significant positive development for Merck, likely to contribute to increased sales and strengthen its competitive position in the oncology market. Given Keytruda's importance to Merck's revenue, this news is expected to have a favorable impact on investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
NEUTRAL IMPACT
Roche Holdings AG's Avastin is mentioned as part of a combination therapy with Merck's Keytruda for cervical cancer, which could indirectly affect Roche's market presence.
While the news is primarily about Merck's Keytruda, Roche's Avastin is mentioned as part of a combination therapy for cervical cancer. This could have an indirect impact on Roche's market presence, but the effect is less direct compared to Merck and the short-term impact on Roche's stock is likely to be neutral.
CONFIDENCE 75
IMPORTANCE 50
RELEVANCE 50